Editorial Material
Medicine, General & Internal
Oladapo O. Yeku, Dan L. Longo
Summary: This editorial discusses the scientific basis of a clinical trial conducted by Prager and colleagues, which tested the efficacy of trifluridine-tipiracil and bevacizumab in treating patients with refractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Medicine, General & Internal
Ting Liao, Li Li, Liya Wang
Summary: This study aims to evaluate the efficacy and safety of bevacizumab combined with chemotherapy in ovarian cancer patients. The results will be analyzed through systematic review and meta-analysis, and published in a peer-reviewed journal.
Review
Reproductive Biology
Chunmei Zhang, Wancheng Zhao
Summary: Angiogenesis inhibitors have shown efficacy and safety in the treatment of recurrent ovarian cancer, improving overall survival, progression-free survival, and objective response rate. However, they may increase the risk of grade >= 3 adverse events.
JOURNAL OF OVARIAN RESEARCH
(2022)
Article
Oncology
Xiaochen Chen, Huafeng Qiu, Yunwang Chen, Mingxing Wang, Pengfei Zhu, Shuangyue Pan, Yaya Deng, Liu Yang, Zheling Chen
Summary: The combination of bevacizumab and TAS-102 has shown better efficacy in treating patients with metastatic colorectal cancer compared to single agent treatment, particularly in terms of overall survival and progression-free survival. However, the dual-drug treatment group had a higher incidence of thrombocytopenia.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Reem D. Mahmood, Danielle Shaw, Tine Descamps, Cong Zhou, Robert D. Morgan, Saifee Mullamitha, Mark Saunders, Nerissa Mescallado, Alison Backen, Karen Morris, Ross A. Little, Susan Cheung, Yvonne Watson, James P. B. O'Connor, Alan Jackson, Geoff J. M. Parker, Caroline Dive, Gordon C. Jayson
Summary: Metastatic colorectal cancer patients receiving standard chemotherapy show changes in cell- and protein-based biomarkers, with no association to survival outcomes. However, an increase in the MRI imaging biomarker K-trans is associated with worse overall survival, indicating potential for directing molecularly targeted therapies.
Article
Oncology
Tianyue Zhai, Takashi Mitamura, Lei Wang, Shimpei I. Kubota, Masaaki Murakami, Shinya Tanaka, Hidemichi Watari
Summary: In this study, combination therapy with BEV and CCR2 inhibitor BMS CCR2 22 was validated to overcome resistance to BEV in ovarian cancer patients. The results showed significant growth suppression in both BEV-sensitive and BEV-resistant patients, and the effect was sustained even after treatment cessation.
Article
Oncology
Young Ju Suh, Banghyun Lee, Kidong Kim, Yujin Jeong, Hwa Yeon Choi, Sung Ook Hwang, Yong Beom Kim
Summary: In women with newly diagnosed ovarian cancer, PARPi may be more effective in terms of PFS compared to bevacizumab, but the risk of serious adverse events is similar between the two treatments.
Article
Oncology
Mirko Fillbrunn, James Signorovitch, Fabrice Andre, Iris Wang, Ines Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo
Summary: This meta-analysis found that PIK3CA mutations were associated with shorter progression-free survival and overall survival in patients with HR+/HER2- mBC. These findings suggest a negative prognostic value of PIK3CA mutations in this patient population.
Review
Pharmacology & Pharmacy
Xiao Han, Pu Ge, Siyu Liu, Dandan Yang, Jinzi Zhang, Xinpei Wang, Weiting Liang
Summary: Bevacizumab combined with chemotherapy may be effective and well-tolerated for patients with unresectable malignant melanoma.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Oncology
Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. S. Hochster
Summary: This meta-analysis indicates that trifluridine/tipiracil plus bevacizumab is more effective and tolerable than trifluridine/tipiracil for refractory metastatic colorectal cancer. Despite the lack of randomized controlled trial data, the results consistently support the use of the combination therapy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Jing Xu, Li'e Sun, Song Luo, Guoqing Zhu, Yilang Zhou, Mei Jiang, Min Wang
Summary: This study evaluated the efficacy and safety of recombinant human endostatin combined with chemotherapy in advanced gastrointestinal tumors in China. The results showed that the short-term efficacy of rh-ES combined with chemotherapy was better, with fewer adverse reactions.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES
(2022)
Article
Oncology
Ming Xie, Yan Zhong, Yide Yang, Fang Shen, Yue Nie
Summary: The study revealed that extended adjuvant endocrine therapy can improve disease-free survival, overall survival, relapse-free survival, distant metastatic-free survival, reduce the incidence of new breast cancer, but also increase the risk of bone fracture and osteoporosis.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Nerea Becerra-Tomas, Katia Balducci, Leila Abar, Dagfinn Aune, Margarita Cariolou, Darren C. Greenwood, Georgios Markozannes, Neesha Nanu, Rita Vieira, Edward L. Giovannucci, Marc J. Gunter, Alan A. Jackson, Ellen Kampman, Vivien Lund, Kate Allen, Nigel T. Brockton, Helen Croker, Daphne Katsikioti, Deirdre McGinley-Gieser, Panagiota Mitrou, Martin Wiseman, Amanda J. Cross, Elio Riboli, Steven K. Clinton, Anne McTiernan, Teresa Norat, Konstantinos K. Tsilidis, Doris S. M. Chan
Summary: Little is known about the impact of diet on breast cancer prognosis. Systematic reviews and meta-analyses were conducted to summarize the evidence on postdiagnosis dietary factors and breast cancer outcomes from randomized controlled trials and observational studies. A total of 108 publications were identified, and the results generally showed limited or no significant associations between diet and breast cancer outcomes, except for some suggestive evidence related to dietary patterns, isoflavone intake, dietary fiber intake, and serum 25-hydroxyvitamin D levels.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Antonio Gonzalez-Martin, Christophe Desauw, Florian Heitz, Claire Cropet, Piera Gargiulo, Regina Berger, Hiroyuki Ochi, Ignace Vergote, Nicoletta Colombo, Mansoor R. Mirza, Youssef Tazi, Ulrich Canzler, Claudio Zamagni, Eva M. Guerra-Alia, Charles B. Levache, Frederik Marme, Fernando Bazan, Nikolaus de Gregorio, Nadine Dohollou, Peter A. Fasching, Giovanni Scambia, Maria J. Rubio-Perez, Tsveta Milenkova, Cristina Costan, Patricia Pautier, Isabelle Ray-Coquard
Summary: Maintenance olaparib plus bevacizumab provided continued benefit beyond first progression in newly diagnosed, advanced ovarian cancer, with a significant improvement in PFS2 and a delay in time to second subsequent therapy or death compared to placebo plus bevacizumab.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
Summary: This study conducted a comprehensive network meta-analysis to determine the optimal adjuvant regional nodal irradiation (RNI) volume for breast cancer (BC) patients, and found that internal mammary node irradiation (IMNI) significantly improved overall survival, disease-free survival, and distant-metastasis-free survival compared to controls. The study also showed that CW/WB+RNI with IMNI was the best treatment approach for BC patients.
FRONTIERS IN ONCOLOGY
(2023)